Business Segments · D&A
Consumer Health — D&A
Over 4 years (FY 2021 to FY 2025), Consumer Health — D&A shows a downward trend with a -100.0% CAGR.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2009
Last reportedQ4 2025Feb 11, 2026
Rolls up toD&A
How to read this metric
Higher levels relative to revenue may indicate an asset-heavy business model or recent significant capital investments that are now being expensed.
Detailed definition
The non-cash expense allocated to the Consumer Health segment to account for the gradual wear and tear of physical asset...
Peer comparison
Standard across all industries; comparable to segment-level D&A reported by any company with distinct operating segments.
Metric ID:
jnj_segment_consumer_health_depreciation_and_amortizationHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $739.00M | $641.00M | $383.00M | $0.00 | $0.00 |
| YoY Change | — | -13.3% | -40.2% | -100.0% | — |
Range$0.00 – $739.00M
CAGR-100.0%
Avg YoY Growth-51.2%
Median YoY Growth-40.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's consumer health — d&a?
- Johnson & Johnson (JNJ) reported consumer health — d&a of $0.00 in Q4 2025.
- What is the long-term trend for Johnson & Johnson's consumer health — d&a?
- Over 4 years (2021 to 2025), Johnson & Johnson's consumer health — d&a has grown at a -100.0% compound annual growth rate (CAGR), from $739.00M to $0.00.
- What does consumer health — d&a mean?
- The periodic cost assigned to the wear and tear of assets used by the Consumer Health segment.